BSEMHealthcare · BiotechnologyThe 1 Wall Street analysts covering BioStem Technologies, Inc. hold a median 12-month price target of $7 — +363.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 27 Oct 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores BioStem Technologies, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Accruals (87): Reported profit is backed by cash, and the company is not expanding recklessly.
Volatility (7): The share price moves around a lot.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BSEM, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +363.6% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 7 Nov 2022 | Zacks Investment Research | Initiates | Buy | $6.40 |
| 7 Nov 2022 | Zacks Investment Research | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BSEM appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 28 Oct 2026, BioStem Technologies, Inc. returned −66.4% against +13.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 70% of US stocks
Cheaper than 72% of US stocks
Cheaper than 70% of US stocks
Cheaper than 69% of US stocks
Higher than 9% of US stocks
Higher than 9% of US stocks
Higher than 74% of US stocks
Higher than 13% of US stocks
Higher than 7% of US stocks
Higher than 17% of US stocks
Higher than 21% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
BioStem Technologies, Inc. has a market value of $28.8M and an enterprise value of $21.7M.
Revenue in the twelve months to 30 June 2026: $132.2M. The latest quarter shrank 27.9% year on year.
Net income over the same four quarters: $7.3M, a 5.5% net margin.
Trailing P/E: 1.8×; forward P/E: 5.3× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
BioStem Technologies, Inc. employs 73 people — $1.8M of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own BioStem Technologies, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
BioStem Technologies announced that Chair and CEO Jason Matuszewski and COO Andrew Van Vurst each exercised options to buy 250,000 shares at $2.00 per share. The 500,000 shares had an aggregate purchase price of approximately $1 million.
Why it matters — The announcement reports that two senior executives invested cash to exercise options and acquire BioStem shares.
BioStem Technologies announced that the USPTO issued one patent and three notices of allowance, and the Mexican Institute of Industrial Property issued one notice of allowance, all related to its placental allograft and umbilical tissue patent portfolio.
Why it matters — This strengthens BioStem's intellectual property protection for its perinatal tissue allograft products in both US and Mexican markets.
BioStem Technologies announced it has entered into definitive agreements for a $3 million private placement, issuing 735,296 shares of common stock alongside Series A and Series B warrants for an additional 735,296 shares each, priced at $4.08 per share at-the-market under Nasdaq rules.
Why it matters — This private placement represents new equity and warrant financing for the regenerative medicine company, which could affect share count and available capital for BSEM watchers.
Terminal1, an operating system built for public companies, announced that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined its platform. The announcement was made via GlobeNewswire on September 21, 2026.
Why it matters — The announcement indicates BioStem Technologies has adopted a new corporate operating platform, which may be of interest to those tracking the company's operational infrastructure and technology choices.
BioStem Technologies announced it has entered into a $40 million Committed Equity Facility (CEF) with Roth Principal Investments, LLC, an affiliate of CR Financial Holdings. The facility, announced on September 18, 2026, provides up to $40 million in committed capital to the regenerative medicine company.
Why it matters — The committed equity facility provides BioStem with access to additional capital, which could support its development and commercialization efforts.
The 1 Wall Street analysts covering BioStem Technologies, Inc. have a median 12-month price target of $7, with estimates ranging from $7 to $7. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 1 analysts covering BioStem Technologies, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks BioStem Technologies, Inc. 59 out of 100 across roughly 4,600 US stocks as at 27 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 27 Oct 2026, BioStem Technologies, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Accruals (87 of 100).
No one can know that. What the data says: the median 12-month target from 1 analysts implies +363.6% from the last close, and Ticker Nerd's factor model ranks BioStem Technologies, Inc. 59 out of 100 as at 27 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering BioStem Technologies, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BSEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $7 to $7 over the next 12 months.
BioStem Technologies, Inc. returned -66.4% over the 12 months to 28 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
BioStem Technologies Inc. is a biotechnology company focused on developing, manufacturing, and commercializing placental-derived allografts for advanced wound care and regenerative therapies.
The most recent item we track (GlobeNewsWire, 8 Oct 2026): "BioStem Technologies' CEO and COO Invest $1 Million in Cash Through Exercise of Stock Options". BioStem Technologies announced that Chair and CEO Jason Matuszewski and COO Andrew Van Vurst each exercised options to buy 250,000 shares at $2.00 per share. The 500,000 shares had an aggregate purchase price of approximately $1 million.
BioStem Technologies Inc. is a biotechnology company focused on developing, manufacturing, and commercializing placental-derived allografts for advanced wound care and regenerative therapies. BioStem Technologies Inc. provides tissue-based solutions used in surgical and wound care settings, with products designed to support soft tissue coverage and repair. Its portfolio includes structural tissue allografts and human connective tissue matrices such as Vendaje, Vendaje AC, Vendaje OPTIC, American Amnion, and American Amnion AC. The company also uses its proprietary BioRetain processing method to preserve the natural properties of perinatal tissue while producing its biologic products. BioStem Technologies Inc. serves clinicians and healthcare providers across specialties where tissue repair and regenerative medicine are used, making it a specialized player in the biologics and wound care market.
CEO Mr. Jason V. Matuszewski · 73 employees · United States · https://biostemtechnologies.com
